Carte­sian clears an au­toim­mune CAR-T tri­al, starts an­oth­er Phase 2 and rais­es $130M

Carte­sian Ther­a­peu­tics, an mR­NA cell ther­a­py biotech, said its lead in­ves­ti­ga­tion­al med­i­cine helped pa­tients with an au­toim­mune con­di­tion that has caught the at­ten­tion of many …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER